Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.
Paleolog
E M
EM
Kennedy Institute of Rheumatology, London, UK.
Fava
R A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D001685:Biological Factors / Q000502:physiology; D001706:Biopsy; D002061:Bursa, Synovial / Q000166:cytology / Q000276:immunology; D018925:Chemokines / Q000032:analysis / Q000494:pharmacology; D005347:Fibroblasts / Q000737:chemistry / Q000187:drug effects; D019084:Fluorescent Antibody Technique, Indirect; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000503:physiopathology* / Q000628:therapy; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000276:immunology; D019030:Receptors, Vitronectin / Q000276:immunology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D018925:Chemokines; D006133:Growth Substances; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D019030:Receptors, Vitronectin